

Rec'd PCT/PTO 08 JUN 2005

P/4639-2

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Date: June 3, 2005

Ilana Helena NATHAN et al.

Confirmation No. 5690

Serial No.: 10/509,405

Group Art Unit: --

Filed: September 24, 2004

Examiner: --

PCT Int'l Appln. No. PCT/IL03/00253

Int'l Filing Date: March 26, 2003

For: COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
NECROSIS

Mail Stop PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES; SUBMISSION
OF SEQUENCE LISTING AND STATEMENT UNDER 37 C.F.R. §1.821(f)

Sir:

Responsive to the Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicant submits herewith a copy of the sequence listing and a computer diskette containing the sequence listing disclosed in the above-identified patent application, a Preliminary Amendment and a Statement in Accordance with 37 CFR §1.821(f). A copy of the Notice is also enclosed.

On information and belief, the content of the enclosed paper and the computer readable form of the sequence listing are the same, and the submission contains no new matter.

It is believed that no fee is required. However, the Patent and Trademark Office is authorized to charge any underpayment to Deposit Account #15-0700.

If this communication is filed after the time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 C.F.R. §1.136(a),

to extend the time for filing a response by the number of months which will avoid abandonment under 37 C.F.R. §1.135. The fee under 37 C.F.R. § 1.17 should be charged to our Deposit Account No. 15-0700.

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label #EV606200871US) in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 3, 2005:

Dorothy Jenkins

Name of Person Mailing Correspondence



Dorothy Jenkins
Signature

June 3, 2005


Date of Signature


Respectfully submitted,


Mark A. Farley
Registration No.: 33,170
OSTROLENK, FABER, GERB & SOFFEN, LLP
1180 Avenue of the Americas
New York, New York 10036-8403
Telephone: (212) 382-0700

DAM:MAF/db/jl

Enclosures

FORM PTO-1390 (REV. 2-2005)		U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER P/4639-2
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/509,405	
INTERNATIONAL APPLICATION NO. PCT/IL03/00253	INTERNATIONAL FILING DATE March 26, 2003	PRIORITY DATE CLAIMED March 26, 2002	
TITLE OF INVENTION COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NECROSIS			
APPLICANT(S) FOR DO/EO/US Ilana (Helena) NATHAN et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. [] This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. [XX] This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. [] This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. [] The US has been elected (Article 31).</p> <p>5. [] A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> a. [] is attached hereto (required only if not communicated by the International Bureau). b. [] has been communicated by the International Bureau. c. [] is not required, as the application was filed in the United States Receiving Office (RO/US). <p>6. [] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <ul style="list-style-type: none"> a. [] is attached hereto. b. [] has been previously submitted under 35 U.S.C. 154(d)(4). <p>7. [] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ul style="list-style-type: none"> a. [] are attached hereto (required only if not communicated by the International Bureau). b. [] have been communicated by the International Bureau. c. [] have not been made; however, the time limit for making such amendments has NOT expired. d. [] have not been made and will not be made. <p>8. [] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. [] An (Executed/Unexecuted) oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. [] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11 to 20 below concern other document(s) or information included:			
<p>11. [] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. [] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. [XX] A preliminary amendment.</p> <p>14. [] An Application Data Sheet under 37 CFR 1.76</p> <p>15. [] A substitute specification.</p> <p>16. [] A power of attorney and/or change of address letter.</p> <p>17. [XX] A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825; Statement in Accordance with 37 C.F.R. 1.821(f) and diskette.</p> <p>18. [] A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. [] A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</p> <p>20. [XX] Other items or information (<i>specify</i>): Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; Copy of Form PCT/DO/EO/922 (371 Formalities Notice) and postcard</p>			
EXPRESS MAIL CERTIFICATE			
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee (mail label #EV606200871US) in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 3, 2005:			
Dorothy Jenkins Name of Person Mailing Correspondence	 Signature		
			June 3, 2005 Date of Signature

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/509,405		INTERNATIONAL APPLICATION NO. PCT/IL03/00253		ATTORNEY'S DOCKET NUMBER P/4639-2	
CALCULATIONS PTO USE ONLY					
The following fees have been submitted					
21. [] Basic national fee..... \$300					
22. [] Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)..... \$100					
All other situations..... \$200					
23. [] Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100					
International Search Report prepared and provided to the Office..... \$400					
All other situations..... \$500					
TOTAL OF 21, 22 and 23 =					
[] Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	/50 =		x \$250	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total Claims	- 20 =	0	x \$ 50	\$	
Independent Claims	- 3 =	0	x \$200	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360	
TOTAL OF ABOVE CALCULATIONS =					
[] Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.					
SUBTOTAL =					
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +					
TOTAL NATIONAL FEE =					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =					
Amount to be refunded: \$					
Amount to be charged: \$0					
a. [] A check (check number _____) in the amount \$_____ to cover the above fees is enclosed. b. [] Please charge my Deposit Account No. 15-0700 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0700. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO: Mark A. Farley, Esq. Ostrolenk, Faber, Gerb & Soffen, LLP 1180 Avenue of the Americas New York, New York 10036-8402			 Registration Number: 33,170 June 3, 2005 Telephone: (212) 382-0700		



UNITED STATES PATENT AND TRADEMARK OFFICE

Re PCT/PTO 08 JUN 2005
COPY

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/509,405	Ilana (Helena) Nathan	P/4639-2
OFGS FILE NO. 214639-2 21-JUNE-2005 PATENTS ORDERED		INTERNATIONAL APPLICATION NO. PCT/IL03/00253 I.A. FILING DATE 03/26/2003 PRIORITY DATE 03/26/2002
CONFIRMATION NO. 5690 371 FORMALITIES LETTER *OC000000015784629*		

Date Mailed: 04/21/2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

APR 25 2005

- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/509,405	PCT/IL03/00253	P/4639-2

FORM PCT/DO/EO/922 (371 Formalities Notice)

COPY